International Thyroid Congress | Conference

John Copland on Patient-Derived Xenografts in Anaplastic Thyroid Cancer

October 27th 2015

John Copland, PhD, faculty member in the department of cancer biology, Mayo Clinic, explains his research on patient-derived xenograft (PDX) models in anaplastic thyroid cancer.

Mayo Study Characterizes Pembrolizumab-Induced Thyroiditis

October 23rd 2015

Abnormal thyroid function tests were reported in up to 15% of patients treated with the PD-1 inhibitor pembrolizumab.

Coexisting BRAF/TERT Mutations Predict Aggressive Thyroid Cancer

October 23rd 2015

Coexisting mutations in BRAF and TERT may be associated with an aggressive phenotype and higher recurrence rates for patients with locally advanced well-differentiated thyroid cancers.

Nodule Size Should Not Determine Biopsy Decision in Thyroid Cancer

October 23rd 2015

The recent American Thyroid Association guidelines to abstain from cytological evaluation by biopsy for patients with thyroid cancer on the basis of having thyroid nodules ≤1 cm is not advisable.

Pazopanib's Activity in Thyroid Cancer Not Predicted by Thyroglobulin

October 22nd 2015

Pazopanib demonstrated significant clinical activity for patients with RAI-refractory differentiated thyroid cancer; however, a predictive biomarker for the therapy could not be uncovered.

Tumor Profiling Identifies Potential Biomarkers for Vandetanib in MTC

October 22nd 2015

Researchers have identified molecular markers in medullary thyroid cancer that were associated with response to vandetanib and the development of metastases.

Dr. Stephen Huang on Challenges in Pediatric Thyroid Cancer

October 22nd 2015

Stephen Huang, MD, Associate Professor of Pediatrics, Harvard Medical School, Dana Farber Cancer Institute, discusses the challenges of pediatric thyroid cancer.

Vemurafenib/Sorafenib Combo Shows Promise in Papillary Thyroid Carcinoma

October 22nd 2015

Dual targeting of BRAF V600E–positive papillary thyroid carcinoma with the anti-BRAF V600E agent vemurafenib and the angiogenesis inhibitor sorafenib showed promising clinical activity.

Dr. Brose on Lenvatinib in Differentiated Thyroid Cancer

October 22nd 2015

Marcia Brose, MD, PhD, associate professor of Otorhinolaryngology, Head and Neck Surgery, at the Hospital of the University of Pennsylvania, discusses survival benefit and possible combination strategies with the lenvatinib in patients with radioactive iodine refractory differentiated thyroid cancer.

Dr. Valderrabano on Understanding Cancer Risk in Indeterminate Thyroid Nodules

October 21st 2015

Pablo Valderrabano, MD, Clinical Research Fellow at Moffitt Cancer Center, discusses molecular markers in thyroid nodules and their connection to cancer incidence.